Roswell Park Research to Headline AACR Annual Meeting: A Glimpse into the Future of Cancer Treatment
Researchers at Roswell Park Comprehensive Cancer Center are set to present groundbreaking work at the American Association for Cancer Research (AACR) annual meeting in San Diego, April 17-22, 2026. The meeting, attracting over 21,000 oncology professionals, promises to showcase the latest advancements in cancer research and treatment strategies.
Targeted Therapy vs. Chemotherapy in Colorectal Cancer: Real-World Evidence Emerges
A retrospective study led by Roswell Park investigators is poised to offer crucial insights into the effectiveness of trastuzumab deruxtecan (T-DXd/Enhertu), a targeted therapy, compared to standard chemotherapy for HER2-positive, microsatellite-stable metastatic colorectal cancer. This aggressive subtype often exhibits limited response to traditional chemotherapy. The study addresses a critical gap in knowledge by tracking overall survival in patients treated with T-DXd outside the controlled environment of clinical trials, considering factors like patient health and prior treatments.
Pro Tip: Real-world data is becoming increasingly critical in oncology. It helps bridge the gap between clinical trial results and everyday patient care, providing a more accurate picture of treatment effectiveness.
Novel Approaches to p53-Mutated Cancers
The TP53 gene, frequently mutated in solid tumors like colorectal and pancreatic cancers, drives tumor progression. Roswell Park researchers have developed a triple-drug regimen demonstrating strong tumor suppression in preclinical models of p53-mutant cancers, without significant toxicity. This combination—trifluridine/tipiracil, talazoparib, and a G2-checkpoint kinase inhibitor—induces uncontrolled DNA damage and cell death in cancer cells.
Breakthroughs in Triple-Negative Breast Cancer Treatment
Metastatic triple-negative breast cancer (mTNBC) remains a formidable challenge due to its aggressive nature and limited treatment options. Preclinical research from Roswell Park reveals a novel combination therapy with the potential to overcome this challenge. The findings, presented as a late-breaking abstract, suggest a promising modern avenue for mTNBC treatment.
Expanding Roles for Roswell Park Researchers at AACR
Beyond presenting research, Roswell Park faculty members are taking on leadership roles at the AACR meeting. Kenan Onel, MD, PhD, will chair a session on population sciences for hematological malignancies. Elizabeth Repasky, PhD, will co-chair a minisymposium on the tumor microenvironment and immune escape. Song Yao, MD, PhD, will co-chair a session on molecular and genetic epidemiology of cancer risk. Yu Fujiwara, MD, will be recognized for completing an AACR-Johnson & Johnson Clinical Oncology Research (CORE) Training Fellowship.
Poster Presentations: A Deep Dive into Roswell Park’s Research
Numerous Roswell Park experts will present their findings through poster presentations, covering a wide range of oncology topics, including prostate cancer, breast cancer, and cancer prevention. These presentations offer detailed insights into specific research areas and potential future directions.
Future Trends in Cancer Research Highlighted at AACR
The Rise of Real-World Data
The Roswell Park study on trastuzumab deruxtecan exemplifies a growing trend: the increasing importance of real-world data in oncology. As clinical trials become more complex and expensive, researchers are turning to data collected from routine clinical practice to assess treatment effectiveness and identify areas for improvement.
Targeting DNA Damage Response
The research on p53-mutated cancers highlights the potential of targeting the DNA damage response pathway. This pathway is often dysregulated in cancer cells, making it a promising target for new therapies. The combination of drugs used in the Roswell Park study demonstrates the power of synergistic approaches.
Personalized Immunotherapy
Several poster presentations touch upon the role of the immune system in cancer. Understanding the interplay between cancer cells and the immune system is crucial for developing effective immunotherapies. Future research will likely focus on identifying biomarkers that predict response to immunotherapy and developing personalized treatment strategies.
The Importance of Multidisciplinary Collaboration
The involvement of Roswell Park researchers in various leadership roles at the AACR meeting underscores the importance of multidisciplinary collaboration in cancer research. Bringing together experts from different fields—oncology, immunology, genetics, and more—is essential for tackling the complex challenges of cancer.
Frequently Asked Questions
- What is the AACR annual meeting? It’s a major international conference where researchers, clinicians, and advocates share the latest discoveries in cancer research.
- What is targeted therapy? Targeted therapy focuses on specific molecules involved in cancer growth and spread, often with fewer side effects than traditional chemotherapy.
- What is the significance of p53 mutations in cancer? TP53 is a tumor suppressor gene, and mutations in this gene are common in many cancers, driving tumor progression.
- What is triple-negative breast cancer? It’s an aggressive subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2, making it demanding to treat.
Did you know? The AACR annual meeting brings together over 21,000 professionals from around the globe, making it one of the largest and most influential cancer research conferences in the world.
Stay informed about the latest advancements in cancer research. Explore more articles on Roswell Park’s website and join the conversation!
